| Literature DB >> 16391802 |
Mari Kuboshima1, Hideaki Shimada, Tian-Ling Liu, Kazue Nakashima, Fumio Nomura, Masaki Takiguchi, Takaki Hiwasa, Takenori Ochiai.
Abstract
We have carried out SEREX (serological identification of antigens by recombinant cDNA expression cloning), and identified SLC2A1 (solute carrier family 2/facilitated glucose transporter, member 1) as an antigen recognized by serum IgG antibodies in patients with esophageal squamous cell carcinoma (SCC). The levels of serum anti-SLC2A1 antibodies (s-SLC2A1-Abs), examined by enzyme-linked immunosorbent assay using bacterially expressed glutathione-S-transferase-SLC2A1 fusion protein, were significantly higher in patients with esophageal SCC than in healthy donors. When using a cut-off level as the mean + 2x standard deviations of healthy donors, a total of 12 (21%) out of 57 SCC patients were revealed as positive for s-SLC2A1-Abs. The presence of s-SLC2A1-Abs was not associated with either clinicopathological factors or survival. Because s-SLC2A1-Abs were not associated with the positivity of other conventional serum markers, a combination assay of s-SLC2A1-Abs with these conventional serum markers may be useful for the diagnosis and monitoring of esophageal SCC.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16391802
Source DB: PubMed Journal: Int J Oncol ISSN： 1019-6439 Impact factor: 5.650